Veritas In Silico (TYO:130A) has launched its first in-house drug project targeting acute kidney injury after cardiovascular surgery, using an mRNA-targeted nucleic acid drug, according to a Monday filing on the Tokyo Stock Exchange.

The treatment, described as first-in-class, targets high-risk patients aged 65 and older in Japan, with peak domestic sales estimated at 15 billion yen.

Development is estimated within eight to 10 years. The drug will be developed using Veritas' ibVIS platform. The company may commercialize the treatment independently or through licensing.